Resistant Pseudomonas Aeruginosa Infections Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Resistant Pseudomonas Aeruginosa Infections Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
- Semi-Synthetic Penicillin
- Cephalosporin
- Lactam Drugs
- Others
Segment by Application
- Hospital
- Clinic
- Home Care
By Company
- ContraFect Corp
- Inhibrx LP
- Achaogen Inc
- LegoChem Biosciences Inc
- Melinta Therapeutics Inc
- Novartis AG
- AmpliPhi Biosciences Corp
- Biolytics Pharma
- Shionogi & Co Ltd
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
